Galmed Pharmaceuticals Ltd. (GLMD) Earnings History
Net Loss14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Galmed Pharmaceuticals Ltd. (GLMD) Earnings Overview
As of June 28, 2026, Galmed Pharmaceuticals Ltd. (GLMD) reported trailing twelve-month net income of -$10M, reflecting +70.4% year-over-year growth. The company earned $-1.57 per diluted share over the past four quarters.
Looking at the long-term picture, GLMD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2012.
Galmed Pharmaceuticals Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), AKBA (-$21M net income, -2.3% margin), HALO ($349M net income, 22.7% margin), GLMD has comparable earnings metrics. Compare GLMD vs MDGL →
GLMD Earnings vs Peers
Earnings metrics vs comparable public companies
GLMD Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$10M | -37.1% | -$9M | $-2.39 | - | - |
| 2024 | -$8M | -8.8% | -$6M | $-8.08 | - | - |
| 2023 | -$7M | +61.3% | -$7M | $-29.95 | - | - |
| 2022 | -$18M | +45.0% | -$18M | $-11.08 | - | - |
| 2021 | -$32M | -12.8% | -$33M | $-19.48 | - | - |
| 2020 | -$29M | -40.6% | -$30M | $-19.46 | - | - |
| 2019 | -$20M | -107.6% | -$22M | $-13.17 | - | - |
| 2018 | -$10M | +19.9% | -$11M | $-8.15 | -483.6% | -525.8% |
| 2017 | -$12M | +27.5% | -$12M | $-14.77 | -1133.5% | -1139.5% |
| 2016 | -$17M | -59.6% | -$17M | $-22.36 | -3630.2% | -3615.0% |
| 2015 | -$11M | -16.7% | -$11M | $-14.35 | - | - |
| 2014 | -$9M | +47.9% | -$9M | $-13.23 | - | - |
| 2013 | -$17M | -455.3% | -$15M | $-24.57 | - | - |
| 2012 | -$3M | - | -$3M | $-9.32 | - | - |
Download Data
Export GLMD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GLMD — Frequently Asked Questions
Quick answers to the most common questions about buying GLMD stock.
What is GLMD earnings per share (EPS)?
GLMD trailing twelve-month (TTM) diluted EPS is $-1.57, reflecting +70.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Galmed Pharmaceuticals Ltd.'s net income?
Galmed Pharmaceuticals Ltd. (GLMD) trailing twelve-month net income is $-10M as of 2025. Earnings grew +70.4% year-over-year.
Is GLMD profitable?
GLMD is not currently profitable on a TTM basis, reporting a net loss of $-10M. Net margin is N/A. Investors should monitor for a return to profitability.
What is GLMD's earnings growth rate?
GLMD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are GLMD's profit margins?
Galmed Pharmaceuticals Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -64.2%.
Is GLMD growing earnings?
Yes, GLMD earnings are accelerating — EPS growth of +70.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-10M. Earnings momentum is strengthening.
What was GLMD's best earnings year?
Galmed Pharmaceuticals Ltd.'s highest annual net income on record is $-3M, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were GLMD's earnings last quarter?
GLMD's most recent reported quarter was Q4 2025. Net income was $-5M with diluted EPS of $-0.73. For a full breakdown of all quarters, see the quarterly earnings table on this page.